On‐treatment alpha‐fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir
Grace L.H. Wong, Henry L.Y. Chan, Yee‐Kit Tse, Hoi‐Yun Chan, Chi‐Hang Tse, Angeline O.S. Lo, Vincent W.S. Wong – 1 October 2013 – Alpha‐fetoprotein (AFP) is the most widely used biomarker for hepatocellular carcinoma (HCC) surveillance, which is criticized as neither sensitive nor specific in active hepatitis and liver cirrhosis. The aim of this study was to determine the performance of AFP as a tumor marker for HCC in entecavir‐treated patients with chronic hepatitis B (CHB).